$394.2 million of service revenue in the second quarter; 17.3% constant currency growth compared to the second quarter of 2015 Second quarter GAAP Net Income per diluted share increased 200.0% to $0.60 [...]
See the latest interactions from our social media
Read the latest updates from our PR department
RALEIGH, N.C., July 18, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its second quarter 2016 results after the market closes on Thursday, July 28. The Company will also [...]
RALEIGH, N.C., May 17, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce that for the third consecutive year it was recognized as the Clinical Research Company [...]
Explore the latest resources uploaded to our media library
Brought to you by PRA Health Sciences. A Bi-Weekly Industry Watch Newsletter
PRA recently performed a feasibility study to identify investigators who see patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial.
PRA Health Sciences provides our clients with innovative solutions for CNS (neurology, psychiatry, and pain) drug development. Our work spans from early phase development to NDA and MAA submissions...
A large pharmaceutical client selected PRA to conduct 2 Phase III epilepsy studies in India, Eastern and Western Europe, and Australia. PRA’s project teams surpassed recruitment goals and achieved timely site activations despite administrative delays and tough competition for volunteers.
Find out what's happening next on PRA's event schedule
The Nordic region is proud to host some of the world’s most innovative biotech, medtech and pharma companies. It also has the 12th strongest economy, making it the perfect place to invest. Set in the idyllic city of Stockholm, the conference offers conference sessions, panel discussions, company presentations, exhibition, face-to-face meetings and unique receptions, providing […]
The 2016 Internation Congress of e-Health Research focuses on how digital technologies disrupt epidemiology and medical research. Its main objectives are to provide an overview of the latest scientific developments and challenges related to the use of ICT in medical research. To reflect on the regulatory, sociological, ethical, logistical and methodological framework for using ICT […]